BC Week In Review | Oct 24, 2016
Company News

Domain Therapeutics, Mavalon Therapeutics deal

Domain formed single-asset, U.K.-based newco Mavalon Therapeutics with an investment of up to EUR9 million ($9.9 million) from Medicxi Ventures . Domain also granted Mavalon rights to positive allosteric modulators of metabotropic glutamate receptor subtype 3...
Items per page:
1 - 1 of 1